IR@PKUHSC  > 北京大学公共卫生学院
学科主题公共卫生
Daclizumab for relapsing remitting multiple sclerosis
Liu, Jia1; Wang, Luning1; Zhan, Siyan2; Tan, Jiping1; Xia, Yinyin2
刊名COCHRANE DATABASE OF SYSTEMATIC REVIEWS
2010
DOI10.1002/14651858.CD008127.pub2
6
收录类别SCI
文章类型Review
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal
研究领域[WOS]General & Internal Medicine
关键词[WOS]DIAGNOSTIC-CRITERIA ; INTERFERON-BETA ; ANTIBODY ; GUIDELINES ; CELLS
英文摘要

Background

The anti-CD25 treatment of daclizumab appears to be effective in patients with relapsing remitting multiple sclerosis (RRMS) as regards clinical and MRI outcomes. Moreover, there are no severe safety concerns arising from clinical testing so far.

Objectives

To assess the efficacy and safety of daclizumab for patients with relapsing remitting multiple sclerosis.

Search strategy

We searched the Cochrane Multiple Sclerosis Group trials register (September 2009), MEDLINE (January 1966 to September 2009), EMBASE (January 1985 to September 2009). At the same time, we handsearched the references quoted in the identified trials, reports (September 2009) from the most important neurological associations and MS Societies in Europe and America, contacted researchers who were participating in trials on daclizumab.

Selection criteria

All randomized controlled clinical trials (RCTs) evaluating daclizumab, alone or combined with other treatments versus placebo, or any other treatment for patients with RRMS. Both parallel group and cross-over designs were included. Data collection and analysis Two reviewers independently assessed references retrieved for possible inclusion. All disagreements were resolved by an independent party. Study authors were contacted for additional information. Adverse effects information was collected from the trials.

Main results

We found no study meeting our inclusion criteria.

Authors′ conclusions

Although studies examining daclizumab for relapsing remitting multiple sclerosis were located, methodologic limitations resulted in the exclusion of all studies. Some of the studies were labelled as crossover trials, however they only compared the effect of different interventions for the same individual. The true randomized crossover trial should compare the effect of different groups, which receive the same intervention, only with the difference in sequence. In other words, the crossover comparison should be between the different groups, rather than on the individual between pretreatment and post treatment. At the same time, all the individuals should be randomly allocated to different groups. There was also a rigorous randomized controlled trial, but the follow-up was shorter than one year (only 44 weeks). In general, daclizumab is safe and well tolerated in combination of interferon treated multiple sclerosis population. Improvements in methodology in future studies are required for meaningful synthesis of data.

语种英语
WOS记录号WOS:000278858300037
引用统计
被引频次:4[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/60754
专题北京大学公共卫生学院
作者单位1.Chinese Peoples Liberat Army Gen Hosp, Dept Geriatr Neurol, Beijing 100853, Peoples R China
2.Peking Univ, Hlth Sci Ctr, Dept Epidemiol & Biostat, Sch Publ Hlth, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Liu, Jia,Wang, Luning,Zhan, Siyan,et al. Daclizumab for relapsing remitting multiple sclerosis[J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS,2010(6).
APA Liu, Jia,Wang, Luning,Zhan, Siyan,Tan, Jiping,&Xia, Yinyin.(2010).Daclizumab for relapsing remitting multiple sclerosis.COCHRANE DATABASE OF SYSTEMATIC REVIEWS(6).
MLA Liu, Jia,et al."Daclizumab for relapsing remitting multiple sclerosis".COCHRANE DATABASE OF SYSTEMATIC REVIEWS .6(2010).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Liu, Jia]的文章
[Wang, Luning]的文章
[Zhan, Siyan]的文章
百度学术
百度学术中相似的文章
[Liu, Jia]的文章
[Wang, Luning]的文章
[Zhan, Siyan]的文章
必应学术
必应学术中相似的文章
[Liu, Jia]的文章
[Wang, Luning]的文章
[Zhan, Siyan]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。